Monte Rosa Therapeutics Stock

Monte Rosa Therapeutics Net Margin

The Net Profit Margin of Monte Rosa Therapeutics (GLUE) as of Jul 26, 2026 is -31.23 %. In the previous year, Net Profit Margin was -96.14 % — a change of -67.51% (higher).

Net Margin

-31.23 %

YoY

-67.51%

Last updated:

Net Profit Margin of Monte Rosa Therapeutics is 2026 -31.23 % . Net Profit Margin of Monte Rosa Therapeutics was 2025 -96.14 % . It decreases by -67.51% higher compared to the previous year.

For Monte Rosa Therapeutics, the net margin of -31.2% is up versus -96.1% a few years ago.

Access this data via the Eulerpool API

Monte Rosa Therapeutics Stock analysis

What does Monte Rosa Therapeutics do? Monte Rosa Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Monte Rosa Therapeutics stock

Net Profit Margin of Monte Rosa Therapeutics is -31.23 % in 2026.

Access this data via the Eulerpool API

Margins — Monte Rosa Therapeutics

All Key Metrics — Monte Rosa Therapeutics